What is an appropriate tapering schedule for a patient on 150 mg of bupropion (Wellbutrin) who needs to wean off?

Wellbutrin 150 mg Tapering Schedule

For a patient on 150 mg of Wellbutrin (bupropion), the FDA-approved discontinuation protocol is to simply stop the medication without tapering, as 150 mg is already the lowest available dose. 11

FDA-Approved Discontinuation Protocol

• The official FDA labeling specifies tapering only for patients on 300 mg daily: decrease to 150 mg once daily prior to discontinuation. 11
• For patients already taking 150 mg daily, no taper is recommended—the medication can be discontinued directly. 11
• This approach is supported by the FDA's dosing guidelines, which identify 150 mg as the starting and lowest therapeutic dose. 1

Clinical Context: When Tapering May Not Be Necessary

• Real-world data indicate that only 8.9% of patients receive a deliberate taper when discontinuing antidepressants, suggesting that the majority of patients tolerate abrupt discontinuation without severe withdrawal symptoms. 2
• Bupropion has a relatively favorable discontinuation profile compared to serotonergic antidepressants (SSRIs/SNRIs), which are more commonly associated with withdrawal syndromes. 2

Alternative Approach: Conservative Taper for High-Risk Patients

If the patient has risk factors for withdrawal symptoms (elderly, renal impairment, history of adverse reactions to medication changes, or prolonged treatment duration), consider a conservative off-label taper:

• Week 1–2: Reduce to 150 mg every other day (75 mg average daily dose).
• Week 3: Discontinue completely.

This approach mirrors the tapering strategy used for the naltrexone/bupropion combination product, which recommends reducing to half the maintenance dose before complete discontinuation. 3

Monitoring During and After Discontinuation

• Monitor for neuropsychiatric symptoms including mood changes, irritability, agitation, insomnia, headache, and dizziness during the first 1–2 weeks after discontinuation. 3
• Assess for return of depressive symptoms, as discontinuation may unmask underlying depression that requires alternative treatment. 3
• Schedule a follow-up visit within 2 weeks of discontinuation to evaluate for withdrawal symptoms or relapse. 3

Special Population Considerations

• Elderly patients with renal impairment may have reduced bupropion clearance and could be at higher risk for withdrawal symptoms; closer monitoring is warranted in this population. 4
• Patients with moderate-to-severe hepatic impairment (who should have been on reduced dosing) require the same approach—direct discontinuation from 150 mg or every-other-day dosing. 1

Common Pitfall to Avoid

• Do not prolong the taper unnecessarily: the "one-size-fits-all" principle for antidepressant discontinuation emphasizes that the first dose reduction is key, and many patients can accelerate thereafter. 2
• Do not confuse bupropion discontinuation with benzodiazepine tapering: unlike benzodiazepines, bupropion does not cause physical dependence requiring gradual dose reduction to prevent dangerous withdrawal. 5